Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epitestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epitestosterone SCHEMBL14034478 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL145157 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL16305625 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13752937 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL11588466 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL2678780 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL12367194 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL21957465 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL22704809 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL17808819 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| US-11707467-B2 | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use | LIPOCINE INC. | 2023-07-25 | — | — | US | claimed |
| CN-115884790-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2023-03-31 | — | — | CN | claimed |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | CONSYNANCE THERAPEUTICS INC (US) | 2023-03-16 | — | — | US | claimed |
| CN-115590966-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司（US） | 2023-01-13 | — | — | CN | claimed |
| CN-115350184-A | Therapeutic combinations of drugs and methods of use thereof | 康圣博施医药有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-4076527-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | Consynance Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | claimed |
| CN-114622228-A | Method for preparing steroid hormone carbonyl intermediate by electrocatalytic oxidation | 浙江工业大学 | 2022-06-14 | — | — | CN | claimed |
| CN-111875655-B | Preparation method of testosterone propionate | 浙江神洲药业有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-111875655-A | Preparation method of testosterone propionate | 浙江神洲药业有限公司 | 2020-11-03 | — | — | CN | claimed |
| US-20050065159-A1 | Penis enlargement | Dr. Kenneth Adams Medicine Professional Corporation (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011705-A1 | ENHANCEMENT OF ERECTILE FUNCTION | ADAMS KENNETH W (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2004011029-A2 | PHARMACEUTICAL COMPOSITIONS FOR PENIS ENLARGEMENT | ADAMS KENNETH W (CA) | 2004-02-05 | — | — | WO | claimed |
| WO-2002092618-A1 | 17 ALPHA-HYDROXY-4-ANDROSTENE-3-ONE AND THE 14, 15-METHYLENE-DERIVATIVES THEREOF | SCHERING AG (DE) | 2002-11-21 | — | — | WO | claimed |
| US-6432939-B1 | SEXUAL DISORDERS | OETTEL MICHAEL (DE) | 2002-08-13 | — | — | US | claimed |
| US-4296233-A | Conjugate of amino sugar-steroid hormone | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-10-20 | — | — | US | claimed |
| US-4220716-A | Process for the preparation of 7α-hydroxylated steroids | HOFFMANN-LA ROCHE INC. (US) | 1980-09-02 | — | — | US | claimed |
| US-4180570-A | 17β-Hydroxy-4-androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | claimed |
| US-4100027-A | Process for the preparation of 4-androstene-3,17-dione derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-07-11 | — | — | US | claimed |
| US-4100026-A | Process for the preparation of 4-androstene-3,17-dione derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | AR 161/4885LMNA 3666/4885CYP3A4 2335/4885 |
| US-20230084144-A1 | THERAPEUTIC COMBINATIONS OF DRUGS AND METHODS OF USING THEM | MCHR1, MCHR2, MC1R | AR 1010/4885LMNA 4569/4885CYP3A4 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.